Aspirin resistance - Clinical daignosis without clear mechanism;Resistens mot acetylsalicylsyra - Klinisk diagnos utan klarlagd mekanism

Lakartidningen

Volumn 101, Issue 45, 2004, Pages 3504-3509

  Hillarp, Andreas ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; IBUPROFEN;

CLINICAL TRIAL; DRUG MECHANISM; DRUG RESISTANCE; GENETIC VARIABILITY; HUMAN; PHARMACEUTICAL CARE; PHENOTYPE; REVIEW; THROMBOCYTE AGGREGATION;

ASPIRIN; BLEEDING TIME; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG TOLERANCE; FIBRINOLYTIC AGENTS; HUMANS; IBUPROFEN; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 8844255583     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110:255-8.
2. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995;2:637-43.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
4. Eikelboom JW, Hankey GJ. Aspirin resistance: A new independent predictor of vascular events. J Am Coll Cardiol 2003;41:906-8.
5. Halushka MC, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Circulation 2002;105:1620-2.
6. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-3.
7. De Gaetano G, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost 2003;1:2048-61.
8. Hankey GJ, Eikelboom JW. Aspirin resistance may be a cause of recurrent ischaemic vascular events in patients taking aspirin. BMJ 2004;328:477-9.
9. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
10. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-7.
11. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105:1650-5.
12. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
13. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: Effects on response to aspirin. Clin Pharmacol Ther 2003;73:122-30.
14. Hillarp A, Lethagen S, Mattiasson I. Aspirin resistance is not a common biochemical phenotype explained by unblocked cyclooxygenase-1 activity. J Thromb Haemost 2003;1:196-7.
15. Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 2003;110:281-6.
16. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5.
17. Hillarp A, Palmqvist B, Lethagen S, Mattiasson I. Mutations within cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 2003; 112:275-83.
18. CAPRIE steering committee. A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39.
19. Catella-Lawson F, Reilly MP, Kapoor SC, Cicchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med 2001;345:1809-17.
20. MacDonald TM, Wie L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-4.